Primary post‐transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients. (25th March 2021)

• Record Type: Journal Article
• Authors: Taj, Mary M.; Maecker‐Kolhoff, Britta; Ling, Rebecca; Bomken, Simon; Burkhardt, Birgit; Chiang, Alan K. S.; Csoka, Monika; Füreder, Anna; Haouy, Stéphanie; Lazic, Jelena; Miakova, Natalia; Minard‐Colin, Veronique; Turner, Suzanne D.; Uyttebroeck, Anne; Attarbaschi, Andishe
• Is Part Of: British journal of haematology. Volume 193:Number 6(2021)
• Page Start: 1178
• Page End: 1184
• Publication Date: 2021-03-25
• Subjects: central nervous system -- outcome -- post‐transplant lymphoproliferative disorder -- transplant -- treatment; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17398
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Primary central nervous system (CNS) post‐transplant lymphoproliferative disorder (PTLD) in childhood is rare. Twenty‐five patients were retrieved from nine European Intergroup for Childhood Non‐Hodgkin's Lymphoma and/or international Berlin–Frankfurt–Münster Study Group members. Types of allografts included kidney ( n = 11), liver ( n = 4), heart ( n = 5), bowel ( n = 1) and haematopoietic stem cells ( n = 4). Eighteen were male, 16 ≥ 10 years old, 21 had monomorphic disease and 24 solid intracranial tumour masses. Four‐year event‐free and overall survival rates were 50% ± 10% and 74% ± 9% respectively. This report represents the largest paediatric series of CNS PTLD reported to date, showing favourable survival odds following systemic and intrathecal chemotherapy and rituximab administration.